key: cord-0026441-2iofnr3w authors: Bestwick, Jason P.; Sharman, Mellora; Whitley, Nat T.; Kisielewicz, Caroline; Skelly, Barbara J.; Tappin, Simon; Kellett‐Gregory, Lindsay; Seth, Mayank title: The use of high‐dose immunoglobulin M‐enriched human immunoglobulin in dogs with immune‐mediated hemolytic anemia date: 2021-11-15 journal: J Vet Intern Med DOI: 10.1111/jvim.16315 sha: f5b3b9201d4d85486c298ac39efb30060570a960 doc_id: 26441 cord_uid: 2iofnr3w BACKGROUND: The IV use of human immunoglobulin (hIVIG) in dogs with primary immune‐mediated hemolytic anemia (IMHA) has been described previously, but herein we describe the use of high‐dose IgM‐enriched hIVIG (Pentaglobin). HYPOTHESIS/OBJECTIVES: Dogs treated with high‐dose Pentaglobin will experience shorter time to remission and hospital discharge and have decreased transfusion requirements compared to dogs receiving standard treatment alone. ANIMALS: Fourteen client‐owned dogs diagnosed with primary IMHA at specialist referral hospitals in the United Kingdom. METHODS: All prospectively enrolled dogs received prednisolone, dexamethasone or both along with clopidogrel. Patients were randomized to receive Pentaglobin at 1 g/kg on up to 2 occasions, or to serve as controls. No additional immunosuppressive drugs were allowed within the first 7 days of treatment. Remission was defined as stable PCV for 24 hours followed by an increase in PCV. RESULTS: Ten of 11 dogs from the treatment group and 2 of 3 dogs from the control group achieved remission and survived until hospital discharge. Survival and time to remission were not significantly different between groups. The volume of packed red blood cells transfused, normalized for body weight, was not significantly different between groups. Potential adverse reactions to Pentaglobin occurred in 2 dogs, but their clinical signs may have been related to the underlying disease. CONCLUSIONS AND CLINICAL IMPORTANCE: Treatment with high‐dose Pentaglobin was well tolerated by dogs with primary IMHA but no significant advantage was found in this small study. Additional studies examining larger groups and subpopulations of dogs with primary IMHA associated with a poorer prognosis are warranted. Human IV immunoglobulin (hIVIG) is created by purification of large volumes of donor plasma. 1 Depending on specific preparations, hIVIG typically contains immunoglobulin G (IgG) as its largest component with smaller and variable amounts of immunoglobulin A (IgA), immunoglobulin M (IgM), cluster of differentiation 4 (CD4), cluster of differentiation 8 (CD8), and human leukocyte antigen molecules. 2 In the United Kingdom, several hIVIG products are available, all of which contain IgG as the primary immunoglobulin component (typically >90%) along with a small amount of IgA and most have IgM as only a negligible or trace fraction of the total immunoglobulin (<0.1 mg/mL). One product, Pentaglobin, is unusual in this respect, being IgM-enriched and containing 50 mg/mL human plasma protein, of which immunoglobulin is at least 95%: 38 mg/mL IgG (76%), 6 mg/mL IgA (12%), and 6 mg/mL IgM (12%). In contrast to IgG that is associated with longer term humoral immunity, but provides more specific immunogenic functions to particular diseases, IgM is associated with polyreactivity, which allows Blymphocytes that can produce IgM to rapidly respond to many antigens. 3 In human medicine, hIVIG is used primarily to manage patients with immunodeficiencies, but it also is used to treat several inflammatory, infectious, and autoimmune diseases. 1, [4] [5] [6] Low doses are administered at regular intervals as replacement therapy for patients with immunodeficiencies whereas high-dose regimens more frequently are used for immunomodulatory treatment of patients with inflammatory or autoimmune diseases. 7 Use of hIVIG in human medicine also has been reported to prevent hemolysis associated with sickle cell disease, and for blood transfusion in patients with lymphoma. 1 Similarly, in veterinary medicine hIVIG has been used for several diseases, 2, 8 including immune-mediated hemolytic anemia (IMHA), [9] [10] [11] [12] [13] immune-mediated thrombocytopenia, [14] [15] [16] cutaneous drug reactions, 17, 18 and myasthenia gravis. 19 The mechanism of action of hIVIG is complex and incompletely understood. Elucidated mechanisms include binding to inhibitory and activating fragment crystallizable (Fc) receptors, downregulation of cytokine synthesis, eradication of autoantibodies, complement inhibition, and mediation of Fas-Fas ligand interactions. 1, 2 Preparations of IgM-enriched hIVIG had superior antiproliferative effects on T-lymphocytes compared to standard hIVIG preparations in an in vitro mouse model. 20 Likewise, in an in vitro human model, Pentaglobin was found to have more potent immunomodulatory capacity than standard hIVIG. 21 There is ongoing interest in its use in people with sepsis, with a meta-analysis indicating that administration to adults with sepsis significantly decreased mortality rates. 22 A concept paper describes its use along with a monoclonal antibody (rituximab) in humans with mucocutaneous blistering diseases 23 and the early use of IgM-enriched hIVIG (Pentaglobin) also appears to decrease the risk of exchange transfusion, as well as the duration of adjunctive phototherapy, in human patients with neonatal immunemediated hemolytic anemia. 24 In dogs with IMHA, the destruction of erythrocytes is believed to represent a type 2 hypersensitivity reaction secondary to the binding of autoantibodies to cell membrane antigens. 25 This binding leads to destruction of the erythrocytes by the mononuclear phagocyte system (extravascular hemolysis) or through complement fixation (intravascular hemolysis). 26 An in vitro study indicated that hIVIG binds to canine lymphocytes and monocytes and inhibits Fc-mediated phagocytosis of autoantibody-opsonized erythrocytes. 27 Hence, in theory, hIVIG may assist in controlling hemolysis secondary to autoantibody opsonization in acute IMHA. Primed erythrocyte-reactive lymphocytes also have been implicated in the pathogenesis of IMHA. 28 Therefore, the aforementioned auxiliary effects of IgM-enriched hIVIG, which may at least in part be a consequence of its interaction with lymphocytes, also might be beneficial in dogs with IMHA. Despite being a common hematological disorder in dogs, 29 beyond initial immunosuppressive treatment with glucocorticoids and the need for thromboprophylaxis, limited evidence supports other treatments. 30 This limited evidence, and associated high cost, has primarily restricted hIVIG to salvage treatment in dogs refractory to standard immunosuppressive protocols, and cost saving considerations often lead to administration at lower doses. Several studies have examined the use of hIVIG in dogs with IMHA, but no general agreement on its use has been reached. 9, 10, 13, 31 These studies have utilized lower doses of hIVIG than doses typically used in human patients where high-dose treatment is preferred for immunomodulation. Our objective was to investigate whether the use of high-dose, IgM-enriched hIVIG would improve the initial response of dogs with IMHA as compared to standard treatment (glucocorticoids and thromboprophylaxis). We hypothesized that high-dose IgM-enriched hIVIG would be safe and effective, and that dogs treated with this product along with standard treatment would experience a shorter time to remission and hospital discharge and have decreased transfusion requirements compared to dogs receiving standard treatment alone. One of the study centers (Animal Health Trust) received a donation of a large volume of IgM-enriched hIVIG that could not be utilized in the human medical field because of regulatory issues. At the time of receipt, only 5 months remained until product expiration. Ours was a prospective, randomized, open-label, controlled study. Enrolled dogs were randomly assigned to either the hIVIG treatment group or control group. Because of limited time before the study drug expiration and a desire to document the effects of the investigation treatment, a case allocation of 2 : 1 (hIVIG treatment group: control group) was utilized. Dogs were allocated by random selection of sealed envelopes that dictated group assignment. Germany) at a dosage of 1 g/kg IV at a fixed infusion rate of 1.7 mL/kg/hour using a syringe driver. During administration of hIVIG, patients were monitored (heart rate, respiratory rate, temperature, and blood pressure) and no other drugs or infusions were administered concurrently. The day of recruitment (also the day of diagnosis) was considered study day 1 for the control and hIVIG treatment groups. When a dog did not achieve stabilization of PCV within 24 hours of the completion of the hIVIG infusion, the same dose was administered on 1 additional occasion. However, if the patient received a blood transfusion immediately after hIVIG infusion, then PCV stability (for the purposes of justifying a second hIVIG infusion) was assessed 24 hours after the end of the blood transfusion. The hIVIG preparation was stored at 4 to 6 C and brought to room temperature before administration. For either treatment group, administration of other immunosuppressive drugs was not allowed within the first 7 days of treatment. The use of additional supportive treatments (eg, IV fluids, blood transfusions, analgesia, gastroprotectants, or antibiotics), however, was allowed at the discretion of attending clinicians. Remission was defined, for the purpose of the study, as stabilization of PCV for 24 hours followed by subsequent increases and lack of requirement for additional blood transfusions. After 7 days, if remission was not achieved, other immunosuppressants could be utilized as deemed appropriate by the attending clinician. Fourteen dogs with nonassociative IMHA were enrolled into the study. Three were assigned to the control group and 11 to the hIVIG treatment group. No enrolled dogs were excluded from the study. No significant difference was found between the control group and hIVIG treatment group in weight, age, sex, or PCV at presentation (Table 1) . Of previously proposed prognostic indicators (increased blood urea nitrogen [BUN] and total bilirubin concentration, decreased platelet count, presence of petechiae and increased band neutrophils), 32, 33 none were statistically different between the 2 groups ( Table 1) . The presence of hemoglobinemia and hemoglobinuria, as markers of intravascular hemolysis, also was not statistically different between groups (Table 1) (Table 2 ). In all dogs that developed stable PCV for 24 hours, PCV subsequently increased and the dogs were discharged without need for additional blood transfusions. In the control group, 2 of 3 dogs achieved remission and survived to hospital discharge ( Our study aimed to evaluate the use of high-dose IgM-enriched hIVIG in dogs with IMHA in a prospective, randomized, controlled manner. In this cohort, we found no significant difference between the treatment and control groups in terms of measured outcome variables. Potential adverse effects to hIVIG were reported in 2 of the 11 dogs that received the treatment. One dog died as a result of these potential complications (sepsis and TED) whereas the other experienced self-resolving tachypnea (suspected TED). However, definitive diagnosis of TED was not obtained in either case, and therefore it is difficult to be certain of this diagnosis. Furthermore, dogs with IMHA are known to already be at increased risk of TED, 34 events in both of these patients makes the relationship to treatment questionable. Adverse effects to hIVIG are reported to occur in 32% of people but are usually mild (fever being most common) and often can be managed by decreasing the infusion rate. 35 As in our study, adverse effects reported in other veterinary studies appear infrequent and include swelling at catheter sites, volume overload, erythema, and anaphylaxis. 13, 19 A hypercoagulable and a proinflammatory state, without clinical signs, also has reported in a small group of experimental dogs that received a single infusion of hIVIG. 36 This observation, along with the known increased risk of TED in dogs with IMHA, suggests that thromboprophylaxis might be particularly crucial in dogs with IMHA that receive hIVIG. In our study, clopidogrel was used on the basis of available literature, affordability, and ease of administration. 37 Of interest in our study was the use of higher than previously utilized doses of hIVIG in dogs. In previous studies, 9, 13 smaller doses were used than in our study. One of these studies was a blinded randomized clinical trial that recruited 28 nonassociative IMHA cases in dogs (14 in the hIVIG treatment group and 14 in the placebo group). 13 The dogs that received hIVIG had 0.5 g/kg administered over 6 hours on 3 consecutive days (1.5 g/kg total dose). The other study was retrospective and included 22 dogs (9 of which were treated with hIVIG) over a 6-year period from a single institution. 9 The dogs that had hIVIG administered received a median dose of 0. 35 Our study was nonblinded, which could have created bias. Blinding and the use of a placebo infusion was considered, but given that fluid overload was a possible risk considered for these IMHA patients, because of the combination of anemia, blood transfusions and potential IV fluid therapy, the addition of an additional nonessential IV transfusion (ie, placebo drug) was not considered safe, ethical, or legal in the United Kingdom. Additionally, remission was considered confirmed by identification of a stable PCV, an objective variable that should be less prone to bias than a subjective outcome. This multicenter prospective study suggested that high-dose IgMenriched hIVIG, in addition to glucocorticoids, is well tolerated by patients but no significant benefits were found compared to glucocorticoids alone in this small cohort. Additional studies utilizing larger groups of dogs with IMHA using a blinded study design and a placebo-controlled group are warranted, in addition to studies examining subpopulations of dogs with IMHA associated with a poorer prognosis to determine if hIVIG treatments would benefit such cases. No funding was received for this study. Presented as a research abstract at the 2018 ACVIM Forum, Seattle, WA. The authors are grateful to the staff of all contributing institutions that aided in the collection of clinical data. We would also like to thank colleagues who took the time to engage in the project but were unsuccessful in recruiting cases during the study period. Clinical uses of intravenous immunoglobulin A review of current indications, adverse effects, and administration recommendations for intravenous immunoglobulin Structure and function of immunoglobulins Intravenous immunoglobulin for Guillain-Barré syndrome The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebocontrolled double-blind clinical trial Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders Use of human intravenous immunoglobulin in veterinary clinical practice Use of human intravenous immunoglobulin in dogs with primary immune mediated hemolytic anemia Intravenous human immunoglobulin for the treatment of immune-mediated hemolytic anemia in 13 dogs Efficacy of the combination of glucocorticoids, mycophenolate-mofetil and human immunoglobulin for the therapy of immune mediated haemolytic anaemia in dogs Prognostic factors and efficacy of human intravenous immunoglobulin G in dogs with idiopathic immune-mediated hemolytic anemia: a retrospective study Use of human immunoglobulin in addition to glucocorticoids for the initial treatment of dogs with immune-mediated hemolytic anemia A prospective, randomized, double-blinded, placebo-controlled study of human intravenous immunoglobulin for the acute management of presumptive primary immune-mediated thrombocytopenia in dogs Treatment of severe immunemediated thrombocytopenia with human IV immunoglobulin in 5 dogs A prospective randomized clinical trial of vincristine versus human intravenous immunoglobulin for acute adjunctive management of presumptive primary immune-mediated thrombocytopenia in dogs Treatment of severe adverse cutaneous drug reactions with human intravenous immunoglobulin in two dogs Erythema multiforme major in a dog treated with intravenous human immunoglobulin and immunosuppressive therapy Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs IgM-enriched human intravenous immunoglobulin suppresses T lymphocyte functions in vitro and delays the activation of T lymphocytes in hu-SCID mice Modulation of alloimmune response in vitro by an IgM-enriched immunoglobulin preparation (Pentaglobin) The clinical efficacy of intravenous IgMenriched immunoglobulin (Pentaglobin) in sepsis or septic shock: a meta-analysis with trial sequential analysis Reversing autoimmunity combination of rituximab and intravenous immunoglobulin The use of Pentaglobulin in neonatal immune hemolytic anaemia In vitro inhibition of canine complement-mediated hemolysis Immune-mediated hemolytic anemia: understanding the nemesis Effects of human intravenous immunoglobulin on canine monocytes and lymphocytes Proliferative responses of peripheral blood mononuclear cells from normal dogs and dogs with autoimmune haemolytic anaemia to red blood cell antigens Systematic review of evidence relating to the treatment of immune-mediated hemolytic anemia in dogs ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs Influence of drug treatment on survival of dogs with immune-mediated hemolytic anemia: 88 cases Predicting outcome in dogs with primary immune-mediated hemolytic anemia: results of a multicenter case registry Idiopathic immune-mediated hemolytic anemia: treatment outcome and prognostic factors in 149 dogs Prothrombotic mechanisms and anticoagulant therapy in dogs with immune-mediated hemolytic anemia Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study Prothrombotic and inflammatory effects of intravenous administration of human immunoglobulin G in dogs A prospective study of clopidogrel therapy in dogs with primary immune-mediated hemolytic anemia High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition Pharmacodynamic and pharmacokinetic evaluation of clopidogrel and the carboxylic acid metabolite SR 26334 in healthy dogs Immune-mediated hemolytic anemia: 70 cases (1988-1996) ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats The effect of blood drawing techniques and equipment on the hemolysis of ED laboratory blood samples Collecting factors related to the haemolysis of blood specimens A comparison of hemolysis rates using intravenous catheters versus venipuncture tubes for obtaining blood samples The use of high-dose immunoglobulin M-enriched human immunoglobulin in dogs with immune-mediated hemolytic anemia Authors declare no conflict of interest. Specific off-label use of antimicrobials did not form part of this prospective study. However, off-label use of antimicrobials may have featured in the management of some of the cases included as deemed appropriate, by the attending clinician on a case-by-case basis.